Nashik, June 03: In a significant milestone for cancer care in North Maharashtra, HCG Manavata Cancer Centre (HCGMCC) has successfully performed its first PIPAC (Pressurized IntraPeritoneal Aerosol Chemotherapy) surgery; an advanced, minimally invasive procedure offering renewed hope to patients with advanced abdominal cancers. The procedure was carried out on a patient diagnosed with advanced stomach cancer, under the guidance of Dr Ninad Katdare from HCG Cancer Centre Mumbai, in collaboration with Prof Dr Raj Nagarkar, MD & Chief of Surgical Oncology and Robotic Services, HCGMCC, who has performed over 70,000 surgeries in his illustrious career.

Originally pioneered by German surgeon Dr Marc Reymond in the early 2000s, PIPAC is now being recognized globally for its ability to manage otherwise inoperable peritoneal cancers including those originating in the stomach, ovaries and colon.

“PIPAC represents a paradigm shift in how we approach advanced abdominal cancers. The breakthrough technique allows chemotherapy to be delivered directly into the peritoneal cavity in aerosolized form using laparoscopic access. The pressurized delivery improves drug penetration, allowing for targeted treatment with minimal systemic side effects. It not only maximizes the therapeutic effect of chemotherapy but also enhances patient comfort and recovery. This successful collaboration between our team at HCG Manavata and HCG Mumbai highlights the power of shared expertise,” says Prof Dr Raj Nagarkar, Chief of Surgical Oncology & Robotic Services and Managing Director - KIMS Manavata Hospitals, HCG Manavata Cancer Centre and Six Sigma, Nashik.

For patients with peritoneal metastases, traditional treatments often yield limited results. PIPAC offers several advantages including targeted therapy, enhanced efficacy, faster recovery and combination potential of pairing with systemic chemotherapy, immunotherapy or radiation.

“The ability to combine PIPAC with other modalities such as systemic chemotherapy and immunotherapy makes it a versatile tool in the oncological arsenal. As surgeons, our learning never ends and embracing new technologies like PIPAC ensures we can deliver the best to our patients. We’re excited about the promise it holds for patients with limited treatment options,” concludes Dr Nagarkar.

About HCG Manavata Cancer Centre (HCGMCC): -

Established in 2007 by Dr Raj Nagarkar, HCGMCC – Nashik is Central India's first NABH-accredited facility. With over 50 consultant oncologists, 900 staff members and a 275-bed capacity, HCGMCC is a leading institution, offering holistic cancer treatment. Specializing in surgical, radiation and medical oncology, the centre has conducted 65,000 surgeries, including 1,400 plus robotic-assisted procedures. Patient-centric and multidisciplinary, HCGMCC recommends treatments to individual needs. Beyond clinical excellence, the centre’s financial aid programs underscore its commitment to accessibility and community well-being, redefining cancer care in the pursuit of a cancer-free future.